Baird analyst David Rescott raised the firm’s price target on Edwards Lifesciences (EW) to $83 from $81 and keeps a Neutral rating on the shares. The firm updated its model following results which saw TAVR growth hit double digits but the TMTT and suspected TAVR deceleration keeps them on the sidelines for now.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $100 from $90 at Mizuho
- Edwards Lifesciences price target raised to $95 from $90 at Piper Sandler
- Edwards Lifesciences price target raised to $96 from $95 at Citi
- Edwards Lifesciences price target raised to $99 from $95 at Barclays
- Edwards Lifesciences Reports Strong Q3 2025 Growth